Coronary artery ectasia (CAE) is a rare disease and a substantial portion of patients with CAE are first diagnosed with acute myocardial infarction (AMI). The question was raised if CAE was a kind of thrombotic disease. We assessed a consecutive series of 119 patients with CAE including 32 patients with AMI (CAE þ AMI group) and 87 patients without AMI (CAE group). During the same period, 90 patients with coronary heart disease, 90 patients with normal coronary arteries (control), and 120 AMI patients without CAE (AMI group) were randomly selected and evaluated. Both current and previous AMI prevalence rates in the CAE population were higher than the AMI rate for the other patients undergoing coronary angiograms; the mean platelet volume and fibrinogen were increased in the CAE þ AMI and CAE groups. For patients with CAE with AMI, most of the thrombotic lesions were in the ectasia site. After dividing the patients with CAE into with and without antiplatelet treatment groups before admission, the AMI rate was lower in the antiplatelet group. Platelets may participate in the thrombotic process in CAE. Antiplatelet treatment may decrease the AMI rate of patients with CAE.
Introduction
Coronary artery ectasia (CAE) is defined as the inappropriate dilatation of a coronary artery, with a luminal diameter 1.5 or more times wider than that of adjacent normal segments. 1 Epidemiological data have shown that the incidence of CAE in patients undergoing coronary angiograms is 1.2% to 7.4%, while the average age of onset is 55 + 10 years, more than 50% of CAE patients have obstructive coronary heart disease (CHD), and the right coronary artery is most frequently involved in the ectatic process. [2] [3] [4] [5] [6] [7] However, as CAE is a rare disease, although several studies have reported that its main clinical manifestations are angina, myocardial infarction (MI), arrhythmia, sudden death, and so on, sufficient understanding of its clinical hazards is still lacking. 2, 4, 8, 9 As the current studies seldom evaluate the clinical characteristics of CAE patients with acute myocardial infarction (AMI), it is not easy to comprehensively determine their clinical significances. In our daily clinical practice, a substantial portion of patients with CAE were first seen in the emergency department and diagnosed with AMI before receiving a coronary angiogram evaluation; rupture of a coronary artery or sudden death was seldom observed throughout the treatment process. Thus, in our limited experience, CAE is more likely to be a kind of thrombotic disease.
This study aimed to answer the question of whether CAE is a high-risk thrombotic disease by systemically reviewing the clinical characteristics of a consecutive series of 119 CAE patients diagnosed by coronary angiogram; to accomplish this, we evaluated the basic clinical characteristics, especially the prevalence of the previous and present AMI event rate, platelets and coagulation system, coronary artery imaging features, and effect of antiplatelet treatment before admission to hospital. We also evaluated the estimated MI size, left ventricular function, and the relationship between ectatic vessel and thrombus site.
Patients and Method Patient Population
In total, 5012 patients underwent coronary angiograms from January 2016 to December 2017 at Beijing Friendship Hospital's cardiac catheterization center. Among these patients, a total of 119 patients with CAE (119/5012, 2.4%) were enrolled in this study, including 32 patients with AMI (CAE þ AMI group) and 87 patients without AMI (CAE group). During the same period, 90 patients with CHD, 90 patients with normal coronary arteries (control), and 120 AMI patients without CAE (AMI group) were randomly selected and evaluated.
The age, sex, and other basic clinical characteristics; platelets and coagulation system; estimated MI size; left ventricular function; and coronary artery imaging features were compared among and between the above groups. This study was approved by the local ethics committee and was in accordance with the Declaration of Helsinki. Informed consent was obtained from all the study participants.
Inclusion Criteria
Each angiogram was interpreted by 2 independent cardiologists and the disagreement was discussed with the expert group of coronary intervention treatment in Beijing Friendship Hospital. Coronary artery ectasia was defined as an ectatic artery diameter exceeding 1.5 times that of adjacent normal segments according to the coronary angiogram evaluation. 9 Coronary heart disease was defined as 50% stenosis in 1 major coronary arteries. 10 Participants with <20% stenosis in coronary arteries were used as controls. A diagnosis of AMI relied on biomarker evidence of myocyte necrosis and electrocardiographic criteria of ischemia or infarction, ischemic symptoms, or both.
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Exclusion Criteria
Exclusion criteria were cardiomyopathy, valvular heart disease, heart failure, aneurysm in other vessels, collagen tissue diseases, vasculitis, syphilis, chronic obstructive lung disease, pulmonary hypertension, early menopause, documented history of hepatic diseases, renal failure, known malignancy, local or systemic infection, previous history of infection (<3 months), other inflammatory diseases, and medications beyond the scope of treatment for CHD that might potentially interfere with measurement of these markers.
Basic Clinical Characteristics
Most of the data in this research were extracted from the medical records, including demographic data (age and sex), disease history (CHD, diabetes, and other diseases), the presence of smoking and drinking, family histories (hypertension, diabetes, and CHD), and medications taken before admission. Body mass index (BMI) was calculated by dividing weight in kg by height in m 2 (kg/m 2 ). The left ventricular ejection fraction was evaluated by transthoracic echocardiography.
Biochemical Analysis
For all patients, the blood samples were analyzed by Clinical Laboratory Department of Beijing Friendship Hospital. The blood samples for platelet parameters were collected in ethylenediaminetetraacetic acid tubes and then measured with the SYSMEX XE-2100 (Kobe, Japan) automated blood counting system; the blood samples for coagulation parameters were collected in sodium citrate anticoagulation tubes and then measured with STAGO STA-R Evolution automated coagulation analyzer (Gennevilliers, France); blood concentrations of muscle-brain type isoenzyme of creatine kinase (CKMB), myoglobin (Myo), troponin I (TnI), and N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured during admission and at 12-hour intervals during the first 5 days following the presentation of AMI (from symptom onset). Serum peak concentrations of the TnI, Myo, and CKMB levels were used for estimations of myocardial infarct size. 12 After 12-hour fasting, blood samples were taken from an antecubital vein to measure total cholesterol (TC), triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol (LDL-C), and fasting plasma glucose levels. For patients without AMI, the above markers were measured on the second day after admission.
Imaging Features of the Coronary Artery
Coronary angiograms were performed via a radial artery approach, without the use of adenosine or a calcium channel blocker. In the Markis classification method, 9 Markis type I refers to diffuse ectasia of 2 or 3 vessels, Markis type II refers to diffuse ectasia in one vessel and localized ectasia in another vessel, Markis type III refers to diffuse ectasia of 1 vessel only, Markis type IV refers to localized or segmental ectasia. The thrombolysis in myocardial infarction frame count of the 3 major coronary arteries which was applied to estimate the coronary blood flow and the Gensini score which was used to evaluate the stenosis extent of coronary atherosclerosis changes were visually determined by an experienced interventional cardiologist according to specified anatomic landmarks and imaging features.
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Statistical Analysis
This research was a case-control study conducted by reviewing the medical data from consecutive series of patients who underwent coronary angiogram evaluation. All analyses were conducted using the Statistical Package for Social Sciences version 26 software (IBM SPSS Statistics, Armonk, New York). All data were initially analyzed using the Kolmogorov-Smirnov test or Shapiro-Wilk test to assess normality. Continuous data are presented as the mean (standard deviation [SD]) when normally distributed and median with interquartile range when non-Gaussian in distribution. Continuous numeric data were tested with a 1-way analysis of variance or Kruskal-Wallis test. Unpaired t tests and Mann-Whitney U rank sum tests were used for bivariate analyses of normally and non-normally distributed continuous data, respectively. The least significant difference method or Nemenyi test was used for multiple comparisons between the groups. Nonparametric data characteristics were assessed as percentage (%) and compared between groups using the w 2 test or Fisher exact test when appropriate. The significance level was set at .05 (2 sided).
Results
In this study, the prevalence of CAE was 2.4% (119/5012) in those who underwent coronary angiogram evaluation, and the prevalence of total CHD (both with and without AMI) was 92.1% (4503/4893) in non-CAE population; the 5 groups comprised 32 CAE patients with AMI (CAE þ AMI), 120 patients with AMI without CAE, 87 patients with CAE, 90 patients with CHD, and 90 control participants. There were 76 patients with CAE with CHD (76/87 ¼ 87.4%) and 29 patients with CAE þ AMI with CHD (29/32 ¼ 90.6%).
The AMI prevalence rate for patients with CAE was 26.9% (32/119), which was higher than the AMI rate for other patients undergoing coronary angiograms (937/4893 ¼ 19.1%, P ¼ .045). The previous AMI rate was 13 .4% for all CAE patients, which was higher than that for the other groups (5.8% for patients with AMI, P ¼ .002; 6.7% for patients with CHD, P ¼ .001), while it was 28.1% for patients with CAE þ AMI, which was also significantly higher than that for the other groups (5.8% for patients with AMI, P ¼ .001; 6.7% for patients with CHD, P ¼ .001).
The other baseline characteristics of the above groups are shown in Table 1 . The 5 groups were balanced in terms of age, sex, presence of hypertension, blood pressure, smoking, alcohol, BMI, serum creatinine, and urea nitrogen and hepatic function. In terms of the rates of CHD history and diabetes, the CAE þ AMI group had a lower rate than the AMI, CAE, and CHD groups did. The lipid profile indicated that TC and LDL-C were increased in the CAE þ AMI and AMI groups compared with the other 3 groups.
As shown in Table 2 , platelets and the coagulation system before admission and estimated AMI infarction size were evaluated in this study. The mean platelet volume (MPV) and fibrinogen (Fbg) levels were increased in the CAE þ AMI and CAE groups. The prothrombin time, activated partial thromboplastin time, fibrin degradation products (FDPs), and D-dimer were increased in the CAE þ AMI group and AMI group, while the prothrombin activity was lower in the CAE þ AMI group. The antiplatelet treatment rate was lower in the CAE þ AMI and AMI groups compared with the CAE and CHD groups.
Myocardial infarction size estimated by the peak concentration of cardiac-specific enzymes, including CKMB, Myo, and TnI, 12 showed that there were no obvious differences between the CAE þ AMI and AMI groups. However, the peak blood NT-proBNP concentration was higher in the CAE þ AMI group. Table 3 summarized the coronary imaging characteristics of the participants enrolled in this study. For the CAE þ AMI patients, 59.4% of the thrombus lesions were situated in the ectasia site. The CAE þ AMI and CAE groups tended to have slower coronary flow than the other 3 groups did. In addition, the Gensini score was higher in the CAE þ AMI group. Other imaging features are listed in the same table. Table 4 showed the differences between the subgroups with and without antiplatelet treatment before admission for patients with CAE. The current AMI rate was significantly lower in patients with CAE on antiplatelet treatment (15.2% vs 34.7%, P ¼ .020). The baseline data listed in the table were balanced between the 2 groups.
Discussion
This study described the clinical characteristics of patients with CAE by analyzing their thrombotic condition and the possible effect of antiplatelet treatment. In this study, most of patients with CAE had CHD and most of the baseline characteristics were balanced among the 5 groups. The level of TC and LDL-C was increased in the CAE þ AMI and AMI populations, as these patients may have a poor lipid control. The research data showed the following results: (1) previous and current AMI rates for the whole CAE population were higher than those of the other patients; (2) for CAE þ AMI patients, most thrombus lesions were located in the ectasia site, and the patients in this subgroup tended to have slower coronary flow and more serious stenosis changes in the coronary artery, while there was no obvious difference for the estimated cardiac infarction size between patients with CAE þ AMI and AMI; (3) for the platelets and coagulation system, the MPV and Fbg were increased in the CAE þ AMI and CAE groups; the changes in other items, such as the D-dimer and FDP in CAE þ AMI and AMI groups, would be secondary to the thrombosis after AMI; and (4) antiplatelet treatment before admission may decrease the AMI rate for patients with CAE.
The most important result in this research was that patients with CAE were exposed to the risk of a thrombotic condition, as indicated by the higher previous and current AMI rates for all the patients with CAE, while the estimated cardiac infarction size for patients with CAE was the same as that of the ordinary patients with AMI. Previous studies have reported that both the AMI history rate and death rate are higher in patients with CAE than in patients with CHD, 15 but patients with CAE with AMI were seldom enrolled and evaluated. Our research provided a more comprehensive evaluation by analyzing all patients with CAE, both with and without AMI, and confirmed that not only the AMI history but also the current AMI rate was higher in CAE populations.
For the patients with CAE þ AMI, most of the involved vessels were situated in ectatic coronary arteries in this study, some researches also showed the expansion site was often the site of thrombus formation (implicated vessels), and the thrombus in the ectatic coronary artery was often large. 4, 16 If patients with CAE had artery thrombotic events, the reperfusion treatment success rate was lower than normal in patients with MI, and a large thrombus could increase the no-reflow phenomenon and distal embolization, as well as the incidence of other adverse events during interventional therapy. 4, 17 After percutaneous coronary intervention, those patients were also prone to have stent thrombosis, restenosis, and migration. Abbreviations: AMI, acute myocardial infarction; APTT, activated partial thromboplastin time; AT-III, antithrombin III; CAE, coronary artery ectasia; CHD, coronary heart disease, CKMB, muscle-brain type isoenzyme of creatine kinase (CKMB); Fbg, fibrinogen; FDP, fibrin degradation product; INR, international normalized ratio; LVEF, left ventricular ejection fraction; MPV, mean platelet volume; Myo, myoglobin; TnI, troponin I; NT-proBNP, N-terminal pro-brain natriuretic peptide; PDW, platelet volume distribution width; PLT, platelet; PT, prothrombin time; PTA, prothrombin activity. a The significance level was .05. Notes for b, c, d, e, f, g, h, i, j: the P values from comparisons between the CAE þ AMI and AMI groups, CAE þ AMI and CAE groups, CAE þ AMI group and CHD groups, CAE þ AMI and control groups, CAE and CHD groups, and CAE and control groups, respectively, were as follows: (b) for the antiplatelet rate before admission: . As for the platelet function, the MPV is a platelet activation marker. 22 Several studies have reported that patients with CAE have a greater peripheral blood MPV [23] [24] [25] [26] ; increased MPV indicates increased platelet reactivity because the large platelet particles associated with more thromboxane A2 and platelet membrane glycoprotein I and IIb/IIIa receptor could promote thrombogenesis. 27 For this reason, antiplatelet therapy has been recommended for CAE. 25 As for the coagulation system, via thrombin, Fbg can be enzymatically converted to fibrin and subsequently a fibrin-based blood clot in the circumstance of tissue and vascular injury. This function is primarily to occlude blood vessels and stop excessive bleeding. 28 However, its significance in CAE is not fully understood. The coronary slow blood flow was an important pathophysiological feature of CAE 29 and could possibly increase the rate of coronary thrombosis embolism. 3 More researches are needed in the future to explore the exact reason for the thrombotic events in CAE.
The third finding in this research was that the AMI rate for patients with CAE was lower if they were treated with an antiplatelet agent. The effect of this treatment further supported that the platelet function may be a prothrombotic factor for patients with CAE and that these patients may benefit from antiplatelet drugs. Until the present, there was no consensus about the treatment for CAE because the exact etiology and pathogenesis of CAE were not fully clarified, and there was a lack of rigorously designed clinical trials. Most of the proposals were based on the treatment of CHD because most patients with CAE also had CHD. According to this research, antiplatelet drugs were an important treatment for patients with CAE. Theoretically, the larger coronary aneurysms require more aggressive treatment by combination of antiplatelet and anticoagulant therapy to reduce thrombosis and coronary artery embolism events because the coagulation system was also abnormal in patients with CAE indicated by the increased Fbg and so on. 30 Thus, this research provided limited evidence that antiplatelet drugs are essential for patients with CAE. More researches are needed in future.
This study has some limitations. Follow-up observations were not used in this study, and differences in major adverse cardiovascular events that occurred at the hospital, including stroke, recurrent MI, heart failure, and cardiovascular death, as well as left ventricular function, could not be fully observed in the short time span of in-hospital treatment. The comparison between antiplatelet treatment and no antiplatelet treatment before admission for patients with CAE was case-control research; a randomized controlled trial is needed to evaluate the importance of antiplatelet treatment.
Conclusions
Coronary artery ectasia is a kind of thrombotic disease. Platelets, the coagulation system, and coronary slow flow may participate in the thrombotic process; antiplatelet treatment may decrease the AMI rate to some degree.
